Amicus Therapeutics Analyst Ratings
Forecasting The Future: 6 Analyst Projections For Corcept Therapeutics
Corcept Therapeutics Analyst Ratings
Unveiling 7 Analyst Insights On Avidity Biosciences
Avidity Biosciences Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $90 Price Target
Crinetics Pharmaceuticals Analyst Ratings
Alkermes Analyst Ratings
Here's How Much You Would Have Made Owning Krystal Biotech Stock In The Last 5 Years
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
How Is The Market Feeling About Krystal Biotech?
Immunovant Stock Falls 8% Amid Graves' Disease Program Update
Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?
Arcellx Analyst Ratings
Top 2 Health Care Stocks That May Collapse This Quarter
Immunovant Reports Phase 2a Results for Graves' Disease Drug, FDA Clears Pivotal Trial
Amicus Started at Buy by Jefferies, Viewed as "Growth at Reasonable Price"
J&J Submits FDA Application for Myasthenia Gravis Drug Nipocalimab
These Are the Stocks With the Largest Changes in Short Interest in July - GS